OpenAI enabled free ChatGPT for verified clinicians in the US

OpenAI launched a program through which verified clinicians in the US — physicians, nurses and technicians, and pharmacists — receive free access to ChatGPT. The program is focused on clinical documentation, patient care workflows, and medical research.

The news is notable because OpenAI is for the first time systematically opening a premium tool to a specific professional group outside of the education sector. Healthcare workers are one of the most time-pressed user categories, and administrative documentation burden is recognized as a leading cause of professional burnout.

How does verification work?

OpenAI conducts verification through partnerships with American medical entities that can confirm a clinician’s status. Details about specific partners are not publicly elaborated in the announcement, but the system resembles models used by other services for B2B verification in healthcare.

The goal of verification is to ensure the tool reaches exactly those for whom it is intended, and not just anyone who claims to be a healthcare worker. This is also important from OpenAI’s economic perspective — free premium access for millions of people without controls would quickly become unsustainable.

What can ChatGPT be used for in healthcare?

OpenAI highlights three areas of application:

• Clinical documentation — summarizing notes, writing reports, formatting discharge letters
• Patient care workflows — preparing patient education materials, organizing schedules, supporting communication
• Medical research — literature review, summarizing studies, assisting in writing scientific papers

It is important to emphasize that ChatGPT is not a replacement for clinical judgment nor a diagnostic tool. US medical regulation (FDA) has strict rules about what constitutes a medical device, and a general chatbot without regulatory clearance does not fall into that category.

What does this mean for healthcare beyond the US?

The program is currently limited to the US. OpenAI has not announced expansion, and EU healthcare systems have different regulatory frameworks (for example, the EU AI Act and MDR) that make replicating the American model more challenging.

Nevertheless, the example is interesting because it shows where OpenAI sees the greatest value for people working under high pressure. If the program shows positive results in clinics, there is a chance that similar approaches will become available in other countries or through local partners.